ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Journal article
Kaplonek P. et al, (2023), Nature immunology
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Preprint
Zhang P. et al, (2023)
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Journal article
Vatzia E. et al, (2023), NPJ Vaccines, 8
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
Journal article
van Doremalen N. et al, (2022), NPJ vaccines, 7
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
Journal article
Cable J. et al, (2022), Annals of the New York Academy of Sciences
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Journal article
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Journal article
van Doremalen N. et al, (2022), Nature Communications, 13
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Journal article
Alharbi NK. et al, (2022), Vaccines, 10
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Journal article
Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Journal article
Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128
Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
Journal article
Evans TG. et al, (2022), The Lancet. Infectious diseases, 22, 857 - 866
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility
Journal article
Rosadas C. et al, (2022), Journal of Virological Methods, 302, 114475 - 114475
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Journal article
Sharpe HR. et al, (2022), JCI Insight, 7
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2022), eBioMedicine, 77, 103902 - 103902
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
Journal article
van Doremalen N. et al, (2022), Res Sq
The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS21-180) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.
Journal article
Utrilla-Trigo S. et al, (2022), Journal of virology, 96
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Journal article
Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
Journal article
Bosaeed M. et al, (2022), The Lancet Microbe, 3, e11 - e20
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Journal article
Lambe T. et al, (2021), Communications Biology, 4
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
Journal article
Spencer AJ. et al, (2021), Nature Communications, 12
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice
Journal article
Collins KA. et al, (2021), Scientific Reports, 11
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
Journal article
Fischer RJ. et al, (2021), Nature communications, 12
No one is safe until we are all safe
Journal article
Gilbert S. and Hatchett R., (2021), Science Translational Medicine, 13
Recombinant protein vaccines against SARS-CoV-2.
Journal article
Gilbert SC. and Lambe T., (2021), The Lancet. Infectious diseases, 21, 1337 - 1338
Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed
Journal article
Figueroa JP. et al, (2021), PLOS Medicine, 18, e1003772 - e1003772
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
Journal article
Bewley KR. et al, (2021), Science Advances, 7
Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.
Journal article
Hotez PJ. et al, (2021), EClinicalMedicine, 39
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Journal article
Madhi SA. et al, (2021), The Lancet HIV, 8, e568 - e580
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Journal article
Butler C. et al, (2021), Vaccines, 9, 851 - 851
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.
Journal article
van Doremalen N. et al, (2021), Science translational medicine, 13
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Journal article
Frater J. et al, (2021), The Lancet HIV, 8, e474 - e485
Transcriptomic profiling of dromedary camels immunised with a mers vaccine candidate
Journal article
Hala S. et al, (2021), Veterinary Sciences, 8
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial
Journal article
Clemens SC. et al, (2021)
Operation Warp Speed: implications for global vaccine security.
Journal article
Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members None., (2021), The Lancet. Global health, 9, e1017 - e1021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
Journal article
Fischer RJ. et al, (2021), bioRxiv
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021)
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies
Journal article
Spencer AJ. et al, (2021)
Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment.
Journal article
Naniche D. et al, (2021), EClinicalMedicine, 36
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Urgent needs to accelerate the race for COVID-19 therapeutics.
Journal article
Batista C. et al, (2021), EClinicalMedicine, 36
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Journal article
Madhi SA. et al, (2021), New England Journal of Medicine, 384, 1885 - 1898
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
Journal article
Marsh GA. et al, (2021), NPJ vaccines, 6
Antibody evasion by the P.1 strain of SARS-CoV-2
Journal article
Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.
Journal article
Watanabe Y. et al, (2021), ACS central science, 7, 594 - 602